PCSK9抑制剂与依折麦布降低心血管事件:按风险分层的临床实践指南
该指南针对已用最大剂量他汀或不耐受他汀且LDL胆固醇>1.8 mmol/L(>70 mg/dL)的成人,按低、中、高、极高心血管风险分层给出弱或强推荐。专家组建议高和极高风险者加用依折麦布或PCSK9抑制剂,低风险者不推荐加用;选择时建议优先依折麦布而非PCSK9抑制剂。
要点
- 已用他汀的极高和高风险成人,建议加用第二种降脂药(弱推荐);低风险者不推荐加用(强推荐)。
- 不耐受他汀的极高和高风险成人,推荐使用降脂药(强推荐);低风险者不推荐加用(强推荐)。
- 需加第二种降脂药时,建议优先选择依折麦布而非PCSK9抑制剂(弱推荐)。
核心结论
- 指南专家组主要给出弱推荐,应用时依赖医患共同决策;低风险者不推荐加用第二种降脂药为强推荐,高和极高风险者加用为强推荐。
研究设计与样本
- 国际专家组(含患者、临床医生和方法学家)遵循可信指南标准并采用GRADE方法制定推荐。
- 专家组将患者分为低、中、高、极高四个心血管风险组,主要从个体患者视角进行证据到推荐的转化。
- 推荐配套交互式证据摘要和决策辅助工具,发布于www.magicapp.org平台。
主要发现
- 关联的系统综述与网络Meta分析(14项试验,83 660名参与者)发现,PCSK9抑制剂或依折麦布可能降低极高和高心血管风险患者的心肌梗死和卒中,对死亡率无影响(中至高质量证据),但在中、低风险患者中无此效果。
- PCSK9抑制剂在降低非致死性心肌梗死或卒中方面可能与依折麦布效果相似(低质量证据)。
- 相对获益一致,但绝对获益随个体心血管风险变化,例如每1000人接受PCSK9抑制剂联合他汀治疗5年,获益从最低风险的减少2例卒中到最高风险的减少21例卒中。
- 两项关于危害的系统综述发现这些药物无重要不良事件(中至高质量证据);PCSK9抑制剂需注射,有时导致注射部位反应(5年期间每1000人最佳估计增加15例)。
关键数值与推荐
- 已用他汀的极高和高风险成人,建议加用第二种降脂药(弱推荐);低风险成人不推荐加用(强推荐)。
- 不耐受他汀的极高和高风险成人,推荐使用降脂药(强推荐);低风险成人不推荐加用(强推荐)。
- 选择加用第二种降脂药时,建议优先选择依折麦布而非PCSK9抑制剂(弱推荐)。
- 已用他汀的极高风险成人,以及不耐受他汀的极高和高风险成人,建议在依折麦布基础上进一步加用PCSK9抑制剂(弱推荐)。
临床怎么用
- 使用推荐前,医生需先识别患者的心血管风险组;建议根据不同地理区域,使用基于已知风险因素组合的可靠风险计算器评估心血管风险。
- 弱推荐反映专家组认为卒中和心肌梗死的小幅减少与负担及有限危害之间接近平衡;因患者价值观和偏好预期变异大,充分知情的决策需要共同决策。
- 交互式证据摘要和决策辅助工具可促进共同决策;可用MATCH-IT决策支持工具与患者互动。
- 医疗系统、临床医生或个人考虑加用依折麦布或PCSK9抑制剂时,可及性和成本将影响决策。
局限性
- 专家组认识到证据中关于患者价值观和偏好的关键不确定性,即多数人认为重要的心血管风险降低与负担和危害相权衡尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CLINICAL QUESTION: In adults with low density lipoprotein (LDL) cholesterol levels >1.8 mmol/L (>70 mg/dL) who are already taking the maximum dose of statins or are intolerant to statins, should another lipid-lowering drug be added, either a proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitor or ezetimibe, to reduce the risk of major cardiovascular events? If so, which drug is preferred? Having decided to use one, should we add the other lipid-lowering drug? CURRENT PRACTICE: Most guidelines emphasise LDL cholesterol targets in their recommendations for prescribing PCSK9 inhibitors and/or ezetimibe in adults at high risk of experiencing a major adverse cardiovascular event. However, to achieve these goals in very high risk patients with statins alone is almost impossible, so physicians are increasingly considering other lipid-lowering drugs solely for achieving LDL cholesterol treatment goals rather than for achieving important absolute cardiovascular risk reduction. Most guidelines do not systematically assess the cardiovascular benefits of adding PCSK9 inhibitors and/or ezetimibe for all risk groups across primary and secondary prevention, nor do they report, in accordance with explicit judgments of assumed patients' values and preferences, absolute benefits and harms and potential treatment burdens. RECOMMENDATIONS: The guideline panel provided mostly weak recommendations, which means we rely on shared decision making when applying these recommendations. For adults already using statins, the panel suggests adding a second lipid-lowering drug in people at very high and high cardiovascular risk but recommends against adding it in people at low cardiovascular risk. For adults who are intolerant to statins, the panel recommends using a lipid-lowering drug in people at very high and high cardiovascular risk but against adding it in those at low cardiovascular risk. When choosing to add another lipid-lowering drug, the panel suggests ezetimibe in preference to PCSK9 inhibitors. The panel suggests further adding a PCSK9 inhibitor to ezetimibe for adults already taking statins at very high risk and those at very high and high risk who are intolerant to statins. HOW THIS GUIDELINE WAS CREATED: An international panel including patients, clinicians, and methodologists produced these recommendations following standards for trustworthy guidelines and using the GRADE approach. The panel identified four risk groups of patients (low, moderate, high, and very high cardiovascular risk) and primarily applied an individual patient perspective in moving from evidence to recommendations, though societal issues were a secondary consideration. The panel considered the balance of benefits and harms and burdens of starting a PCSK9 inhibitor and/or ezetimibe, making assumptions of adults' average values and preferences. Interactive evidence summaries and decision aids accompany multi-layered recommendations, developed in an online authoring and publication platform (www.magicapp.org) that also allows re-use and adaptation. THE EVIDENCE: A linked systematic review and network meta-analysis (14 trials including 83 660 participants) of benefits found that PCSK9 inhibitors or ezetimibe probably reduce myocardial infarctions and stroke in patients with very high and high cardiovascular risk, with no impact on mortality (moderate to high certainty evidence), but not in those with moderate and low cardiovascular risk. PCSK9 inhibitors may have similar effects to ezetimibe on reducing non-fatal myocardial infarction or stroke (low certainty evidence). These relative benefits were consistent, but their absolute magnitude varied based on cardiovascular risk in individual patients (for example, for 1000 people treated with PCSK9 inhibitors in addition to statins over five years, benefits ranged from 2 fewer strokes in the lowest risk to 21 fewer in the highest risk). Two systematic reviews on harms found no important adverse events for these drugs (moderate to high certainty evidence). PCSK9 inhibitors require injections that sometimes result in injection site reactions (best estimate 15 more per 1000 in a 5 year timeframe), representing a burden and harm that may matter to patients. The MATCH-IT decision support tool allows you to interact with the evidence and your patients across the alternative options: https://magicevidence.org/match-it/220504dist-lipid-lowering-drugs/. UNDERSTANDING THE RECOMMENDATIONS: The stratification into four cardiovascular risk groups means that, to use the recommendations, physicians need to identify their patient's risk first. We therefore suggest, specific to various geographical regions, using some reliable risk calculators that estimate patients' cardiovascular risk based on a mix of known risk factors. The largely weak recommendations concerning the addition of ezetimibe or PCSK9 inhibitors reflect what the panel considered to be a close balance between small reductions in stroke and myocardial infarctions weighed against the burdens and limited harms.Because of the anticipated large variability of patients' values and preferences, well informed choices warrant shared decision making. Interactive evidence summaries and decision aids linked to the recommendations can facilitate such shared decisions. The strong recommendations against adding another drug in people at low cardiovascular risk reflect what the panel considered to be a burden without important benefits. The strong recommendation for adding either ezetimibe or PCSK9 inhibitors in people at high and very high cardiovascular risk reflect a clear benefit.The panel recognised the key uncertainty in the evidence concerning patient values and preferences, namely that what most people consider important reductions in cardiovascular risks, weighed against burdens and harms, remains unclear. Finally, availability and costs will influence decisions when healthcare systems, clinicians, or people consider adding ezetimibe or PCSK9 inhibitors.
引用
- Hao Q, Aertgeerts B, Guyatt G, et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. BMJ. 2022. PMID: 35508320. doi:10.1136/bmj-2021-069066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。